Disability Benefits for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

How SSA Evaluates CIDP Under Listing 11.14

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long-lasting disorder in which the immune system attacks the protective covering of the peripheral nerves, causing progressive or relapsing weakness, numbness, and loss of reflexes. It is sometimes described as a chronic form of Guillain-Barré syndrome. SSA evaluates CIDP under Blue Book listing 11.14 for peripheral neuropathy, which can be met in one of two ways.

• 11.14A — disorganization of motor function. An extreme limitation in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities, meaning major, lasting loss of movement control in at least two limbs.
• 11.14B — physical plus mental limitation. A marked limitation in physical functioning together with a marked limitation in one area of mental functioning, such as concentrating and keeping pace or managing yourself.

Because CIDP is chronic and can relapse and remit, SSA looks at the pattern of symptoms over time rather than a single visit. The medical record should show the weakness and sensory loss in the arms and legs and how they limit standing, walking, and hand use. Treatment such as immunotherapy can help, so SSA considers whether significant limitations remain despite it. Fatigue and nerve pain, which often accompany CIDP, are part of the overall picture.

Medical Evidence for a CIDP Claim

These claims rest on a firm diagnosis plus documentation of lasting deficits. SSA will look for:

• Diagnostic testing — nerve conduction studies and EMG showing demyelination, spinal fluid analysis, and sometimes a nerve biopsy.
• Exam findings — muscle weakness, reduced or absent reflexes, and sensory loss in the arms and legs, tracked over time.
• Treatment records — immunotherapy such as IVIG, steroids, or plasma exchange, and how you responded.
• Functional notes — how the weakness and numbness limit walking, standing, balance, and hand use.

Ask your neurologist to describe your function between and during relapses — how far you can walk, how long you can stand, and what your hands can do — and whether treatment has fully controlled the disease. Because CIDP fluctuates, evidence that significant limitations persist over time, even with treatment, is what makes the claim persuasive.

Qualifying Through an RFC Assessment

When CIDP does not meet listing 11.14, SSA assesses residual functional capacity (RFC). Weakness and numbness in the legs limit standing, walking, and climbing and may require a cane, walker, or braces, while involvement of the arms and hands limits gripping, lifting, and fine manipulation. Loss of sensation can affect balance and the safe handling of objects.

Nerve pain and the fatigue that often comes with CIDP reduce stamina and concentration across a workday, and relapses can cause unpredictable periods of worse function and absences. Time spent receiving infusions or other treatment can also interfere with a work schedule. SSA builds these limits into an RFC — often sedentary work with limited standing, walking, and hand use, plus extra breaks — and compares it to your past jobs. If you cannot return to that work, the medical-vocational grid rules may direct a finding of disabled, particularly for claimants age 50 and older.

Tips for a Stronger CIDP Claim

• Get objective testing. Nerve conduction studies and EMG showing demyelination firmly establish the diagnosis.
• Document the fluctuating course. Record both relapses and your baseline function so SSA sees the ongoing impact.
• Show limits despite treatment. Evidence that weakness persists even with immunotherapy strengthens the claim.
• Report fatigue and nerve pain, which add to your limitations.
• Note treatment time. Regular infusions can interfere with a work schedule and are worth documenting.